🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Any benefit w/ upfront SRS for EGFR and ALK positive NSCLC brain Mets treated w/CNS penetrant TKI? · ↑↑LC and CNS control · No diff OS · 10% symptomatic RN after SRS ascopubs.org/doi/10.1200/JC…

Also want to mention my gratitude for the opportunity to work on this study w/ outstanding collaborator & lead author Luke Pike (The Pike Lab), Emily Miao, MD, PharmD, & 7 center TURBO-NSCLC team Tejas Patil Brandon Imber Tony Wang @njmyall1 Nicholas J Thomas, MD Joshua D. Palmer, MD Brian Kavanagh

A new multi-institution study from The Pike Lab and colleagues in Journal of Clinical Oncology finds adding up-front stereotactic radiosurgery improved time to CNS progression in patients with brain metastases from EGFR- and ALK-driven non-small cell lung cancer. #NSCLC bit.ly/3WDgwcF

🧠⚡️🫁☢️New in Journal of Clinical Oncology from The Pike Lab Chad Rusthoven: The addition of up-front #radiation #SRS to CNS-penetrant #TKI ⬆️time-to-CNS progression & local control (but not OS) in pts with brain mets from #EGFR #ALK-driven #NSCLC #lungcancer. #lcsm #radonc ascopubs.org/doi/10.1200/JC…

Any role of up-front SRS in lung pts with brain Mets and EGFR or ALK targetable mutations who is receiving the 3th generation TKIs? JCO July 24, 2024 SRS improves time to CNS progression, particularly for lesion > 1 cm OS is similar MDT and personalized approach are crucial.

Online now at European Urology Oncology is exciting work by Jennifer Ma, MD Luke del Balzo Henry Walch, co-mentored with Ritesh Kotecha. The largest series of RCC BM genomics, identifying genomic biomarkers correlated with CNS outcome after SRS. Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Radiation Oncology doi.org/10.1016/j.euo.…

Clinical Outcomes and Targeted Genomic Analysis of Renal Cell Carcinoma Brain Metastases Treated with Stereotactic Radiosurgery - European Urology Oncology euoncology.europeanurology.com/article/S2588-…

Proud to see work led by Chengcheng Gui and Henry Walch published in Journal of Neurosurgery in which we examine radiosurgical outcomes in a large cohort of CRC BM patients. Dose matters here and we identify putative genomic biomarkers. Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Radiation Oncology thejns.org/view/journals/…

4 years residency, friends for life ❤️ #HROP #ASTRO24

We're hiring again this year for an MSK CNS Fellow! Please directly inquire if interested! careers.astro.org/job/fellowship…

From the November issue: Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection. bit.ly/4eujN3K By Peter Mazzone, Victor Velculescu,The Pike Lab Cleveland Clinic Johns Hopkins Kimmel Cancer Center Memorial Sloan Kettering Cancer Center DELFI Diagnostics

I am very pleased to partner with Harbinger Health in our combined goal of making blood-based early cancer detection a reality! Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Radiation Oncology harbinger-health.com/2024/11/07/har…

I'm pleased to share work led by Ben Gaeta and Jordan Eichholz Jordan Eichholz on CNS outcomes and genomic correlates of KRAS mutant NSCLC Brain Mets treated with SRS, published in the Red J! Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Radiation Oncology IJROBP - The Red Journal sciencedirect.com/science/articl…

The ICON-RT study is now active at MSK! In this ph2 RCT, we seek to test a treatment de-escalation strategy for EGFR+LC Brain Mets through Intracranial CONsolidation with RT after a lead-in of osimertinib-based therapy! Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Radiation Oncology clinicaltrials.gov/study/NCT06741…

What is the optimal integration of SRS and CNS-active TKIs for brain metastases from EGFR & ALK+ NSCLC? New JAMA Oncology clinical evidence summary for this controversial topic The Pike Lab jamanetwork.com/journals/jamao…

I’m pleased to share our summary of the clinical evidence on the use of TKIs and SRS in EGFR or ALK+ NSCLC! We need better biomarkers to select patients for treatment de-escalation. JAMA Oncology Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Radiation Oncology jamanetwork.com/journals/jamao…

The management of brain metastases in EGFR-variant and ALK-positive NSCLC patients remains uncertain, with evidence suggesting that upfront stereotactic radiosurgery (SRS) offers better local control and delays CNS progression. ja.ma/3G3SdyM

Consensus Radiation Treatment Planning Guidelines Using (68)Ga-DOTATATE PET/CT For Resected Meningiomas - International Journal of Radiation Oncology, Biology, Physics redjournal.org/article/S0360-… Kudos to Joshua D. Palmer, MD Haley K. Perlow, MD for leading this effort!